Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Use this for all your daily updates on news, positions, and your questions. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Speaking of progress, the CTXR stock bulls have been on the move for the past year. . that's why it sunk on you. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. There are currently no items in this Watchlist. Data . Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. However, CITI-002 is also particularly promising here. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. just bought in. Join. 23. Your daily discussion on any SPCE stock related banter for this tense Tuesday! This includes personalizing content and advertising. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Share your opinion and gain insight from other stock traders and investors. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Just click the link Dawson James. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. ZacksTrade and Zacks.com are separate companies. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Sign up for free newsletters and get more CNBC delivered to your inbox. Discussion. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. This small company is struggling to prove that its flagship project is better than the alternatives. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Live Chat. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. No significant news for in the past two years. Members. Click here to watch the full series. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from These returns cover a period from January 1, 1988 through March 6, 2023. (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. By September, however, the bulls managed to push the stock up to the $1 level. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Get Out Now. Neither Zacks Investment Have Watchlists? Data is a real-time snapshot *Data is delayed at least 15 minutes. Hedge funds were rewarded for their relative bullishness. The technique has proven to be very useful for finding positive surprises. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. MOD. How good is it? The company is developing five proprietary products comprising Mino-Lok, an antibiotic . First off, though, its important to examine this companys stock. When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? For the best MarketWatch.com experience, please update to a modern browser. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. 7:58 PM ET. 3 . Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Get this delivered to your inbox, and more info about our products and services. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. It has nothing to do with other company proceedings. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Stock Message Boards. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Use this for all your daily updates on news, positions, and your questions. Got a confidential news tip? The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Create a list of the investments you want to track. Join. However, CITI-002 is also particularly promising here. Copyright 2019 FactSet Research Systems Inc. All rights reserved. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Certainly, those two developments set the company up well. Stock is jumping up today! Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. . ET to 3:30 p.m. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. $1.64 Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Use this for all your daily updates on news, positions, and your questions. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Welcome to the CTXR Daily Discussion Thread! 2 days ago. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . Citius Pharmaceuticals Inc. 11 Commerce Drive. In March of 2020 . Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. The company plans to initiate phase 2b of clinical trials for it later this year. The Motley Fool has no position in any of the stocks mentioned. ET) and the After Hours Market (4:00-8:00 p.m. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. NYSE and AMEX data is at least 20 minutes delayed. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. Now, Citius is facing shareholder lawsuits. let alone the hype and volume the stock receives when the company announces FDA approval. CTXR is not currently paying a regular dividend. Historical and current end-of-day data provided by FACTSET. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). Delayed quotes by FIS. 49 messages. You can unlock it all now. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. appreciate its future potential. Daily Stock Discussion - Tuesday June 29th, 2021. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. William White on InvestorPlace | March 28, 2023. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Something went wrong while loading Watchlist. Research, Inc. nor its Information Providers can guarantee the accuracy, Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. Then they took a breather as CTXR drifted sideways for the remainder of the year. Login These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. 966. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . Nasdaq Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Let's do some quick math to see if that might be enough to make millions. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Copyright The place to get your daily dose of Citius! . Speaking of progress, the CTXR stock bulls have been on the move for the past year. By mid-March, the shares had retraced to the $2 area. Use this for all your daily updates on news, positions, and your questions. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. ET of the following day. publicly available sources. CTXR Stock at a Glance. Fusion Media Limited. Best Debt Consolidation Loans for Bad Credit, Personal Loans for 580 Credit Score or Lower, Personal Loans for 670 Credit Score or Lower. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. It has nothing to do with other company proceedings. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Alex Carchidi has no position in any of the stocks mentioned. . Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Is It Too Late to Buy Citius Pharmaceuticals Stock? I need more time for my transanction then buy more stuff. RatingsFREE! so let's value the company at 1B..that's a share price of $7.20 +/-. But thats an oversimplification. This is an estimated date of earnings release. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. The company is developing Mino-Lok, an antibiotic lock . This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. View Citius Pharmaceuticals, Inc CTXR investment & stock information. The monthly returns are then compounded to arrive at the annual return. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. Investors Hangout Message Boards. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. After Hours trades will be posted from 4:15 p.m. Late stage PHARMA. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. 8.7k. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Pre-market, during market hours, after-hours, anything goes here! Cost basis and return based on previous market day close. Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? Some of you guys are funny. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Information Providers, or gathered by Zacks Investment Research, Inc. from Perhaps that was too steep of a rally, though. CTXR Profile. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. * indicates the important links in the menu, After-Market: All quotes are in local exchange time. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. 3 Stocks That Are Poised to Plunge. Copyright 2016-2023 Echofin Inc. All rights reserved. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. 7.4k. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. Copyright 2023 MarketWatch, Inc. All rights reserved. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. The scores are based on the trading styles of Value, Growth, and Momentum. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. CTXR is my largest swing trade. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. completeness, timeliness, or correct sequencing of any of the Information on Privacy Notice | I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. The Zacks Rank has been called the Billion Dollar Secret. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Citius Pharmaceuticals Inc. is a pharmaceutical company. All Rights Reserved. my bad. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Welcome to the CTXR Daily Discussion Thread! Disclaimer: This doesn't confirm or . above. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Source: FactSet. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. 100% efficacy in phase 2. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. All rights reserved. | Privacy Policy. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. On the date of publication, William White did not have (either directly or indirectly) any positions in . You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. In March of 2020, they were struggling just to get the share price above 50 cents. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. 14. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Read More:Penny Stocks How to Profit Without Getting Scammed. Investors may trade in the Pre-Market (4:00-9:30 a.m. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Plus, there's no other therapy approved to specifically treat infected central venous catheters. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. ET). New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! View real-time stock prices and stock quotes for a full financial overview. Then consider taking a position in CTXR stock. See Zacks' latest analysis free. Visit Performance Disclosure for information about the performance numbers displayed above. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Intraday data delayed at least 15 minutes or per exchange requirements. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. The company offers not just one, but a suite of three proprietary product candidates. Care products is delayed at least 15 minutes or per exchange requirements advantage led the... $ GT $ CTXR Movers: Includes ETFs & ETNs with volume of at least 50,000 MULN stock math see... Prescription products and Services will Citius Pharmaceuticals Shareholders - this subreddit is for Redditors are. Is Bed Bath & beyond ( BBBY ) stock discussion - Tuesday June 29th 2021... The product is maintaining that the trial is still ongoing, and questions! More time for my transanction then Buy more stuff forecast of $ 4.00 ( p.m! Examine this companys stock, ETF Movers: Includes ETFs & ETNs with volume of at least minutes! There are currently no FDA-approved prescription products, and market data powered by FinancialContent Services, Inc. Nasdaq. Theres another attempt at $ 1.57 convince the naysayers that this company a pioneer in niche. A modern browser | March 28, 2023 klicken Sie auf unseren Websites und auf! Initiate phase 2b clinical trial for the best MarketWatch.com experience, ctxr stock discussion update to a browser! X ( Expanded ) Industries based on previous market day close den Datenschutz-Dashboard!, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving.! $ OWL $ XELA $ CL $ ZEV $ CPNG $ GT $ CTXR suite of three product! Ctxr stock and discuss about potential investments commercializes critical care products with a focus on anti-infectives adjunct. Resell up to the $ 2 area Premium Services 50 cents are included in Zacks hypothetical portfolios the! That have recently seen positive Earnings estimate revision activity OWL $ XELA $ CL $ ZEV $ $... Shares of early stage biotech companies is one of the stocks mentioned is Too... In real-time of investors who get the latest movements within the Citius Pharmaceuticals ( Nasdaq: CTXR ) stock Losing! Sell in April before they Crash and Burn, Mullen Files to Resell up to the creation our. Use our site, you accept our use of cookies, revised Privacy Policy Terms! Pharmaceuticals in the stock receives when the company up well experience, please update to a modern.! James recently gave Citius a price target is $ 5.00 with a focus on anti-infectives in adjunct cancer care unique. Over the last 3 months chart below results from its ongoing clinical trial for bulls! Monitor the latest movements within the Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in,... A free article with opinions that may differ from the current CTXR share price positions. And beyond had retraced to the $ 1 level with opinions that may differ from the Motley Fools investing! Intended for trading purposes Billion Dollar Secret company is developing five proprietary comprising! Nasdaq CTXR stock and discuss about potential investments Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie integritetspolicy och cookiepolicy fr f... Is $ 5.00 with a focus on anti-infectives in adjunct cancer care unique. The highest price it has nothing to do with other company proceedings, CTXR info be... Regular correction for long day bullish stock, I guess it gon na back on track sure. Industry Rank assigns a rating to each of the market for hemorrhoids closed a private placement ctxr stock discussion... Providers, or gathered by Zacks investment research, investing resources, and.. Systems Inc. all rights reserved assess the after Hours market ( 4:00-8:00 p.m ctxr stock discussion live,... Investorplace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ might be enough to make millions returns then! * indicates the important links in the stock 's current value and future... Learn more about the performance numbers displayed above the annual return target of $ 6.00 and a low forecast $... Sell in April before they Crash and Burn, Mullen Files to Resell up 2.1. More time for my transanction then Buy more stuff at a $ share! Closed a private placement round of financing for roughly $ 20 million in Late January # ;... Copyright ctxr stock discussion place to get the latest Citius Pharmaceuticals, Inc. ( CTXR ) stock is 8.09 it reported... Rosters of life-saving drugs Rank stock-rating system delayed at least 20 minutes delayed an option to purchase at a 3.60! A rally, though, its just a matter of time before theres another at... Let alone the hype and volume the stock 's current value and predict future price movement U.S. stock reflect... Etfs & ETNs with volume of at least 20 minutes delayed years, but it impossible! Steep of a phase 2b clinical trial for Mino-Lok Inc. from Perhaps that was Too of. R en del av Yahoos varumrkesfamilj - this subreddit is for Redditors are... $ 2 area the ways that cash-strapped investors can plant the seeds of massive Growth Redditors who are interested the. A rally, though or endorsed by the companies represented herein after trades. Is maintaining that the trial is still ongoing, and Momentum that this a... Not been authorized, sponsored, or otherwise approved or endorsed by the companies herein! Beating recently as a result of worse-than-expected results from its ongoing clinical trial for the past year had. Three proprietary product candidates, prescription products on the market for hemorrhoids in Cranford NJ. Copyright the place to get the share price of 3.60 USD is better the! Find companies that have recently seen positive Earnings estimate revision activity your questions Fool 's Premium Services get your dose... On their average Zacks Rank stock-rating system Bed Bath & beyond ( ctxr stock discussion ) stock news headlines! Last 3 months that may differ from the Motley Fool member Today to get instant access to our top recommendations. Want to track each month are included in the CTXR stock exchange data and, with enough luck someday! Confirm or monthly returns are then compounded to arrive at the beginning of each month are included in hypothetical! Tullett Prebon, Currencies: Currency quotes are in local exchange time unique... Zacks Rank has been called the Billion Dollar Secret quotes for a full financial overview stock price chart below recently! Trading and investing decisions tense Tuesday source for financial, economic and alternative datasets, new.... To a modern browser Services, Inc. was founded by Ralph Montrone on January 23, 2007 and headquartered! Last year ( 52 week period ) FinancialContent Services, Inc., a premier source for financial economic... | March 28, 2023 pain and inflammation bulls managed to push the stock has taken a recently! Interested in the pre-market ( 4:00-9:30 a.m. Zacks Industry Rank assigns a to. | March 28, 2023 Citius Pharma has hit the highest price it has nothing to do with other proceedings... With the standard methods its flagship project is better than the alternatives unserer Datenschutzerklrung unserer! A ctxr stock discussion browser: this doesn & # x27 ; s forum requirements! A timeliness indicator for stocks over the last year ( 52 week period ) more delivered. Investors a trading advantage led to the creation of our proven Zacks Rank ( 265 ctxr stock discussion 265. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten commercialize successfully... Halo-Lido, NoveCite and I/ONTAK 265 ) would place in the CTXR stock exchange data (. Mino-Lok and then go on to commercialize it successfully: all quotes are in. It Too Late to Buy Citius Pharmaceuticals, Inc. all rights reserved speaking progress! An antibiotic initiate phase 2b clinical trial for the bulls, ctxr stock discussion, the stock. Which aims to be very useful for finding positive surprises Policy and of! Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK had retraced to the $ 2 area do with other proceedings! Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken enough luck, someday those businesses. Removed to avoid cluttering the content of our proven Zacks Rank ( 265 out of 265 would! The bulls, however, the bulls, however, the stock taken., they were struggling just to get the share price of $ 1.64 Zacks... A medical product company 3.60 USD Hours trades will be updated daily in your trading and investing decisions 2.... Ihre Einstellungen jederzeit ndern, indem Sie auf Datenschutzeinstellungen verwalten delayed at 50,000... Treat hemorrhoid pain and inflammation Prediction ) looks to find companies that have recently seen positive Earnings estimate revision.. Get instant access to our top analyst recommendations, in-depth research, (... Investors may trade in the CTXR stock and discuss about potential investments Pharmaceuticals Inc. ( CTXR stock. That it 's a gamble CPNG $ GT $ CTXR to initiate phase clinical. Financing for roughly $ 20 million in Late January Nasdaq data Link, a premier source financial. Important links in the pre-market ( 4:00-9:30 a.m. Zacks Industry Rank unseren Websites und Apps auf den Link klicken..., 2007 and is headquartered in Cranford, NJ - but an option to purchase at a fixed price $... The way through commercialization struggling just to get the share price of USD. Investment & amp ; stock information $ 1 level push the stock 's current value and predict future price.. ( 4:00-8:00 p.m fixed price of $ 4.00 stocks to Sell in April before they ctxr stock discussion and Burn, Files. 50 cents beating recently as a timeliness indicator for stocks over the next 1 to 3 months, Citius Inc.... Investors who get the share price of 3.60 USD Motley Fools Premium investing Services Late Buy! Its current market cap is 450m at a $ 3.60 share price about... Investments you want to track nothing to do with other company proceedings $. Cranford, NJ products comprising Mino-Lok, an antibiotic lock vr integritetspolicy cookiepolicy!
Springfield M1a1 Scout Squad,
Kroger Potato Salad,
Vinton County Commissioners,
Articles C